Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126108293 | 12610829 | 3 | F | 201601 | 20160822 | 20160801 | 20160902 | PER | US-PFIZER INC-2016327190 | PFIZER | 79.00 | YR | F | Y | 0.00000 | 20160902 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126108293 | 12610829 | 1 | PS | TIKOSYN | DOFETILIDE | 1 | 250 UG, UNK | N | 20931 | 250 | UG | CAPSULE, HARD | |||||||
| 126108293 | 12610829 | 2 | SS | TIKOSYN | DOFETILIDE | 1 | 0.25 MG, UNK | N | 20931 | .25 | MG | CAPSULE, HARD | |||||||
| 126108293 | 12610829 | 3 | C | ELIQUIS | APIXABAN | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126108293 | 12610829 | 1 | Supraventricular tachycardia |
| 126108293 | 12610829 | 2 | Atrial fibrillation |
| 126108293 | 12610829 | 3 | Supraventricular tachycardia |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126108293 | 12610829 | Dizziness | |
| 126108293 | 12610829 | Visual impairment |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126108293 | 12610829 | 1 | 201511 | 0 | ||
| 126108293 | 12610829 | 2 | 20151110 | 0 | ||
| 126108293 | 12610829 | 3 | 20151110 | 0 |